Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Keyword: Dysphagia

Publisher: Associated Press

Published: May 22, 2026

RAHWAY, N.J.--(BUSINESS WIRE)--May 22, 2026-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agencys Committee for Medicinal Products… [+80304 chars]

Read Full Story ↗